Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,392.00
(
0.08%
)
News Focus
News Focus
Post# of 257300
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: isolution post# 1070

Monday, 02/09/2004 1:27:55 AM

Monday, February 09, 2004 1:27:55 AM

Post# of 257300
Two more PR’s on oral Tazarotene in psoriasis, which make the case that Tazarotene is considerably safer than other retinoid drugs for chronic use:

http://biz.yahoo.com/prnews/040207/nysa004_1.html

http://biz.yahoo.com/prnews/040207/nysa001a_1.html

These studies in psoriasis will presumably bolster the safety data to support an FDA application to use oral Tazarotene in AMD (as previously discussed on this board).



“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today